Cargando…

Buprenorphine initiation strategies for opioid use disorder and pain management: A systematic review

Buprenorphine possesses many unique attributes that make it a practical agent for adults and adolescents with opioid use disorder (OUD) and/or acute or chronic pain. Sublingual buprenorphine has been the standard of care for treating OUD, but its use in pain management is not as clearly defined. Cur...

Descripción completa

Detalles Bibliográficos
Autores principales: Spreen, Lauren A., Dittmar, Emma N., Quirk, Kyle C., Smith, Michael A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9310825/
https://www.ncbi.nlm.nih.gov/pubmed/35302671
http://dx.doi.org/10.1002/phar.2676
_version_ 1784753473696301056
author Spreen, Lauren A.
Dittmar, Emma N.
Quirk, Kyle C.
Smith, Michael A.
author_facet Spreen, Lauren A.
Dittmar, Emma N.
Quirk, Kyle C.
Smith, Michael A.
author_sort Spreen, Lauren A.
collection PubMed
description Buprenorphine possesses many unique attributes that make it a practical agent for adults and adolescents with opioid use disorder (OUD) and/or acute or chronic pain. Sublingual buprenorphine has been the standard of care for treating OUD, but its use in pain management is not as clearly defined. Current practice guidelines recommend a period of mild‐to‐moderate withdrawal from opioids before transitioning to buprenorphine due to its ability to displace full agonists from the μ‐opioid receptor. However, this strategy can lead to negative physical and psychological outcomes for patients. Novel initiation strategies suggest that concomitant administration of small doses of buprenorphine with opioids can avoid the unwanted withdrawal associated with buprenorphine initiation. We aim to systematically review the buprenorphine initiation strategies that have emerged in the last decade. Embase, PubMed, and Cochrane Databases were searched for relevant literature. Studies were included if they were published in the English language and described the transition to buprenorphine from opioids. Data were collected from each study and synthesized using descriptive statistics. This review included 7 observational studies, 1 feasibility study, and 39 case reports/series which included 924 patients. The strategies utilized between the literature included traditional initiation (47.9%), microdosing with various buprenorphine formulations (16%), and miscellaneous methods (36.1%). Traditional initiation and microdosing initiation were compared in the data synthesis and analysis; miscellaneous methods were omitted given the high variability between methods. Overall, 95.6% of patients in the traditional initiation group and 96% of patients in the microdosing group successfully rotated to sublingual buprenorphine. Initiation regimens can vary widely depending on patient‐specific factors and buprenorphine formulation. A variety of buprenorphine transition strategies are published in the literature, many of which were effective for patients with OUD, pain, or both.
format Online
Article
Text
id pubmed-9310825
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-93108252022-07-29 Buprenorphine initiation strategies for opioid use disorder and pain management: A systematic review Spreen, Lauren A. Dittmar, Emma N. Quirk, Kyle C. Smith, Michael A. Pharmacotherapy Review of Therapeutics Buprenorphine possesses many unique attributes that make it a practical agent for adults and adolescents with opioid use disorder (OUD) and/or acute or chronic pain. Sublingual buprenorphine has been the standard of care for treating OUD, but its use in pain management is not as clearly defined. Current practice guidelines recommend a period of mild‐to‐moderate withdrawal from opioids before transitioning to buprenorphine due to its ability to displace full agonists from the μ‐opioid receptor. However, this strategy can lead to negative physical and psychological outcomes for patients. Novel initiation strategies suggest that concomitant administration of small doses of buprenorphine with opioids can avoid the unwanted withdrawal associated with buprenorphine initiation. We aim to systematically review the buprenorphine initiation strategies that have emerged in the last decade. Embase, PubMed, and Cochrane Databases were searched for relevant literature. Studies were included if they were published in the English language and described the transition to buprenorphine from opioids. Data were collected from each study and synthesized using descriptive statistics. This review included 7 observational studies, 1 feasibility study, and 39 case reports/series which included 924 patients. The strategies utilized between the literature included traditional initiation (47.9%), microdosing with various buprenorphine formulations (16%), and miscellaneous methods (36.1%). Traditional initiation and microdosing initiation were compared in the data synthesis and analysis; miscellaneous methods were omitted given the high variability between methods. Overall, 95.6% of patients in the traditional initiation group and 96% of patients in the microdosing group successfully rotated to sublingual buprenorphine. Initiation regimens can vary widely depending on patient‐specific factors and buprenorphine formulation. A variety of buprenorphine transition strategies are published in the literature, many of which were effective for patients with OUD, pain, or both. John Wiley and Sons Inc. 2022-03-25 2022-05 /pmc/articles/PMC9310825/ /pubmed/35302671 http://dx.doi.org/10.1002/phar.2676 Text en © 2022 The Authors. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy published by Wiley Periodicals LLC on behalf of Pharmacotherapy Publications, Inc https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Review of Therapeutics
Spreen, Lauren A.
Dittmar, Emma N.
Quirk, Kyle C.
Smith, Michael A.
Buprenorphine initiation strategies for opioid use disorder and pain management: A systematic review
title Buprenorphine initiation strategies for opioid use disorder and pain management: A systematic review
title_full Buprenorphine initiation strategies for opioid use disorder and pain management: A systematic review
title_fullStr Buprenorphine initiation strategies for opioid use disorder and pain management: A systematic review
title_full_unstemmed Buprenorphine initiation strategies for opioid use disorder and pain management: A systematic review
title_short Buprenorphine initiation strategies for opioid use disorder and pain management: A systematic review
title_sort buprenorphine initiation strategies for opioid use disorder and pain management: a systematic review
topic Review of Therapeutics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9310825/
https://www.ncbi.nlm.nih.gov/pubmed/35302671
http://dx.doi.org/10.1002/phar.2676
work_keys_str_mv AT spreenlaurena buprenorphineinitiationstrategiesforopioidusedisorderandpainmanagementasystematicreview
AT dittmaremman buprenorphineinitiationstrategiesforopioidusedisorderandpainmanagementasystematicreview
AT quirkkylec buprenorphineinitiationstrategiesforopioidusedisorderandpainmanagementasystematicreview
AT smithmichaela buprenorphineinitiationstrategiesforopioidusedisorderandpainmanagementasystematicreview